Богородская Елена Михайловна – директор Государственного бюджетного учреждения здравоохранения города Москвы «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы», главный внештатный специалист фтизиатр Департамента здравоохранения города Москвы, заведующая кафедрой фтизиатрии Федерального государственного бюджетного образовательного учреждения дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации, доктор медицинских наук, профессор
Адрес: 107076, г. Москва, ул. Стромынка, д. 10.
Тел. +7(499) 268-00-05;
e-mail: BogorodskayaEM@zdrav.mos.ru
Литвинов Виталий Ильич – научный руководитель Государственного бюджетного учреждения здравоохранения города Москвы «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы», доктор медицинских наук, профессор, академик РАН
Адрес: 107076, г. Москва, ул. Стромынка, д. 10.
Тел. +7(499) 268-04-15;
e-mail: mnpcbtlv@yandex.ru
1. Богородская Е.М., Слогоцкая Л.В., Шамуратова Л.Ф., Севостьянова Т.А. Cкрининг туберкулезной инфекции у детей и подростков на основе
применения двух внутрикожных тестов: с туберкулином и аллергеном туберкулезным рекомбинантным (ESAT-6/CFP-10) в Москве в 2021 г. //
Туберкулез и болезни легких. – 2022. – Т.100 – №11. – С. 29-38. https://doi.org/10.21292/2075-1230-2022-100-11-29-38
2. Земскова З.С., Дорожкова И.Р. Скрыто протекающая туберкулезная инфекция //М: Изд. Медицина. – 1984. – 222 с.
3. Каграманов А.И. Скрытая туберкулезная инфекция и ее значение в патогенезе и иммунитете /Дисс. … д-ра мед. наук. – М. – 1952.
4. Киселев В.И., Барановский П.М., Пупышев С.А. и др. Новый кожный тест для диагностики туберкулеза на основе рекомбинантного
белка ESAT-CFP // Молекулярная медицина. – 2008. – № 4. – с. 4–6.
5. Литвинов В.И., Слогоцкая Л.В., Сельцовский П.П. и др. Новый кожный тест для диагностики туберкулезной инфекции. // Российский
медицинский журнал. – М. – 2009. – № 1. – С. 52–56.
6. Литвинов В.И. Латентная туберкулезная инфекция: свойства возбудителя; реакция макроорганизма; эпидемиология и диагностика
(IGRA-тесты, ДИАСКИНТЕСТ® и другие подходы) / В.И. Литвинов. – М.: МНПЦБТ. – 2016. – 196 с.
7. Митинская Л.А. Туберкулинодиагностика. Руководство по внутренним болезням. – М.: Медицина. – 1996. – С. 95-102.
8. Митинская Л.А. Туберкулез у детей. – М:ЗАО «Кудесники». – 2004. – 196 с.
9. Скворцов Т.А., Ажикина Т.Л. Адаптивные изменения экспрессии генов Mycobacterium tuberculosis в ходе инфекционного процесса // Биоорг. Химия. – 2012. – Т. 38. – С. 391-405.
10. Слогоцкая Л.В., Литвинов В.И., Филиппов А.В. и др. Чувствительность нового кожного теста «ДИАСКИНТЕСТ®» при туберкулезной инфекции
у детей и подростков. // Пробл. туб. и болезней легких. – М. – 2010. – № 1. – С. 10–15.
11. Слогоцкая Л.В., Богородская Е.М., Шамуратова Л.Ф., Севостьянова Т.А. Эффективность скрининга туберкулезной инфекции у детей и
подростков в г. Москве в 2019 г. на основе нового алгоритма применения внутрикожной пробы с аллергеном туберкулезным рекомбинантным
(ESAT-6/CFP-10) / Туберкулез и болезни легких. – 2021. – Т. 99, № 1. – С. 15-25. http://doi. org/10.21292/2075-1230-2021-99-1-15-25.
12. Abel L, Fellay J, Haas DW, Schurr E, Srikrishna G, Urbanowski M, Chaturvedi N, Srinivasan S, Johnson DH, Bishai WR. Genetics of human susceptibility
to active and latent tuberculosis: present knowledge and future perspectives. Lancet Infect Dis. 2018 Mar;18(3):e64-e75. doi: 10.1016/S1473-3099(17)30623-0.
13. Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016
Feb 3;5(2):e10. doi: 10.1038/emi.2016.10.
14. Anton C, Machado FD, Ramirez JMA, Bernardi RM, Palominos PE, Brenol CV, Mello FCQ, Silva DR. Latent tuberculosis infection in patients with rheumatic diseases. J Bras Pneumol. 2019 Apr 25;45(2):e20190023. doi: 10.1590/1806-3713/e20190023.
15. Baggaley RF, Vegvari C, Dimala CA, Lipman M, Miller RF, Brown J, Degtyareva S, White HA, Hollingsworth TD, Pareek M. Health economic analyses of
latent tuberculosis infection screening and preventive treatment among people living with HIV in lower tuberculosis incidence settings: a systematic review.
Wellcome Open Res. 2023 Jan 5;6:51. doi: 10.12688/wellcomeopenres.16604.2.
16. Bergstedt W, Tingskov PN, Thierry-Carstensen B, Hoff ST, Aggerbeck H, Thomsen VO, Andersen P, Andersen AB. First-in-man open clinical trial
of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent. PLoS One. 2010 Jun 25;5(6):e11277. doi: 10.1371/journal.pone.0011277.
17. Bibbins-Domingo K, Grossman DC, Curry SJ, Bauman L, Davidson KW, Epling JW Jr, García FA, Herzstein J, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phillips WR, Phipps MG, Pignone MP. Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016 Sep 6;316(9):962-9. doi: 10.1001/jama.2016.11046.
18. Boom WH, Schaible UE, Achkar JM. The knowns and unknowns of latent Mycobacterium tuberculosis infection. J Clin Invest. 2021 Feb 1;131(3):e136222.
doi: 10.1172/JCI136222.
19. Brites D, Gagneux S. Co-evolution of Mycobacterium tuberculosis and Homo sapiens. Immunol Rev. 2015 Mar;264(1):6-24. doi: 10.1111/imr.12264.
20. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific
interferon-gamma test. Respir Res. 2006 Apr 1;7(1):56. doi: 10.1186/1465-9921-7-56.
21. Carranza C, Pedraza-Sanchez S, de Oyarzabal-Mendez E, Torres M. Diagnosis for Latent Tuberculosis Infection: New Alternatives. Front Immunol.
2020 Sep 10;11:2006. doi: 10.3389/fimmu.2020.02006.
22. Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, Parkhill J, Malla B, Berg S, Thwaites G, Yeboah-Manu D, Bothamley G, Mei J, Wei L, Bentley S, Harris SR, Niemann S, Diel R, Aseffa A, Gao Q, Young D, Gagneux S. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet. 2013 Oct;45(10):1176-82. doi: 10.1038/ng.2744.
23. Dale KD, Karmakar M, Snow KJ, Menzies D, Trauer JM, Denholm JT. Quantifying the rates of late reactivation tuberculosis: a systematic review. Lancet
Infect Dis. 2021 Oct;21(10):e303-e317. doi: 10.1016/S1473-3099(20)30728-3.
24. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, Lange C, Losi M, Markova R, Migliori GB, Nienhaus A, Ruhwald M, Wagner D, Zellweger JP, Huitric E, Sandgren A, Manissero D. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J. 2011 Jan;37(1):88-99. doi: 10.1183/09031936.00115110.
25. Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, Ma S, Meermeier E, Lewinsohn DM, Sherman DR. Incipient and Subclinical
Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clin Microbiol Rev. 2018 Jul 18;31(4):e00021-18. doi: 10.1128/CMR.00021-18.
26. Dutta NK, Karakousis PC. Latent tuberculosis infection: myths, models, and molecular mechanisms. Microbiol Mol Biol Rev. 2014 Sep;78(3):343-71.
doi: 10.1128/MMBR.00010-14
27. Esmail H, Barry CE 3rd, Young DB, et al.. The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci 2014; 369: 20130437.
doi: 10.1098/rstb.2013.0437.
28. Esmail H, Cobelens F, Goletti D. Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. Eur Respir J
2020; 55: 1901957. doi: 10.1183/13993003.01957-2019.
29. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015 May 28;372(22):2127-35.
doi: 10.1056/NEJMra1405427.
30. Gong W, Wu X. Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy. Front
Microbiol. 2021 Oct 22;12:745592. doi: 10.3389/fmicb.2021. 745592.
31. Halliday A, Whitworth H, Kottoor SH, Niazi U, Menzies S, Kunst H, Bremang S, Badhan A, Beverley P, Kon OM, Lalvani A. Stratification of Latent
Mycobacterium tuberculosis Infection by Cellular Immune Profiling. J Infect Dis. 2017 May 1;215(9):1480-1487. doi: 10.1093/infdis/jix107.
32. Hamidieh F, Farnia P, Nowroozi J, Farnia P, Velayati AA. An Overview of Genetic Information of Latent Mycobacterium tuberculosis. Tuberc Respir Dis
(Seoul). 2021 Jan;84(1):1-12. doi: 10.4046/trd.2020.0116.
33. Harries AD, Kumar AMV, Satyanarayana S, Takarinda KC, Timire C, Dlodlo RA. Treatment for latent tuberculosis infection in low- and middle-income
countries: progress and challenges with implementation and scale-up. Expert Rev Respir Med. 2020 Feb;14(2):195-208. doi: 10.1080/17476348.2020.1694907.
34. Joshi H, Kandari D, Bhatnagar R. Insights into the molecular determinants involved in Mycobacterium tuberculosis persistence and their therapeutic
implications. Virulence. 2021 Dec;12(1):2721-2749. doi: 10.1080/21505594.2021.1990660.
35. Johnson PD, Stuart RL, Grayson ML, Olden D, Clancy A, Ravn P, Andersen P, Britton WJ, Rothel JS. Tuberculin-purified protein derivative-, MPT-64-, and
ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clin Diagn Lab Immunol. 1999 Nov;6(6):934-7. doi: 10.1128/CDLI.6.6.934-937.1999.
36. Kanabalan RD, Lee LJ, Lee TY, Chong PP, Hassan L, Ismail R, Chin VK. Human tuberculosis and Mycobacterium tuberculosis complex: A review on genetic
diversity, pathogenesis and omics approaches in host biomarkers discovery. Microbiol Res. 2021 May;246:126674. doi: 10.1016/j.micres.2020.126674.
37. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, Yim JJ. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma
assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA. 2005 Jun 8;293(22):2756-61.
doi: 10.1001/jama.293.22.2756.
38. Kendall EA, Shrestha S, Dowdy DW. Reply to: subclinical tuberculosis: some flies in the ointment. Am J Respir Crit Care Med 2021; 203: 1328–1329.
doi: 10.1164/rccm.202102-0367LE
39. Khabibullina NF, Kutuzova DM, Burmistrova IA, Lyadova IV. The Biological and Clinical Aspects of a Latent Tuberculosis Infection. Trop Med Infect Dis.
2022 Mar 8;7(3):48. doi: 10.3390/tropicalmed7030048.
40. Kik S., Schumacher S., Cirillo D., Churchyard G., Boehme C., Goletti D. et al. An evaluation framework for new tests that predict progression
from tuberculosis infection to clinical disease. Eur Respir J. 2018 Oct 25;52(4):1800946. doi: 10.1183/13993003.00946-2018. PMID: 30139776.
41. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O‘Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers
for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017 Jan 15;64(2):111-115.
doi: 10.1093/cid/ciw778.
42. Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol. 2010 Jul 1;185(1):15-22. doi: 10.4049/jimmunol.0903856.
43. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, Bossink A, Magdorf K, Hölscher C, Kampmann B, Arend SM, Detjen A, Bothamley G, Zellweger JP, Milburn H, Diel R, Ravn P, Cobelens F, Cardona PJ, Kan B, Solovic I, Duarte R, Cirillo DM; C. Lange; TBNET. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009 May;33(5):956-73. doi: 10.1183/09031936. 00120908.
44. Mao L, Xu L, Wang X, Du J, Sun Q, Shi Z. et al. Use of DosR and Rpf antigens from Mycobacterium tuberculosis to screen for latent and relapse tuberculosis infection in a tuberculosis endemic community of Huainan City. Eur J Clin Microbiol Infect Dis. 2022 Jul;41(7):1039-1049. doi: 10.1007/s10096-022-04459-8.
45. Martinez L, Arman A, Haveman N, Lundgren A, Cabrera L, Evans C. et al. Changes in tuberculin skin test positivity over 20 years in periurban shantytowns
in Lima, Peru. Am J Trop Med Hyg. 2013;89(3):507–515. doi: 10.4269/ajtmh.13-0005.
46. Meier N., Jacobsen M., Ottenhoff T., Ritz N. A Systematic Review on Novel Mycobacterium tuberculosis Antigens and Their Discriminatory Potential
for the Diagnosis of Latent and Active Tuberculosis. Front Immunol. 2018 Nov 9;9:2476. doi: 10.3389/fimmu.2018.02476.
47. Menardo F, Duchêne S, Brites D, Gagneux S. The molecular clock of Mycobacterium tuberculosis. PLoS Pathog. 2019 Sep 12;15(9):e1008067.
doi: 10.1371/journal.ppat. 1008067.
48. Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, et al.. Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people
living with HIV: a prospective diagnostic and prognostic accuracy study. Lancet Glob Health 2021; 9: e841–e853. doi: 10.1016/S2214-109X(21)00045-0.
49. Migliori GB, Nardell E, Yedilbayev A, et al.. Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. Eur Respir J 2019; 53: 1900391. doi: 10.1183/13993003.00391-2019.
50. Migliori GB, Ong CWM, Petrone L, D‘Ambrosio L, Centis R, Goletti D. The definition of tuberculosis infection based on the spectrum of tuberculosis disease. Breathe (Sheff). 2021 Sep;17(3):210079. doi: 10.1183/20734735.0079-2021.
51. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and
middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2008 Jun;8(6):359-68. doi: 10.1016/S1473-3099(08)70071-9.
52. Nasreen S, Shokoohi M, Malvankar-Mehta MS. Prevalence of Latent Tuberculosis among Health Care Workers in High Burden Countries: A Systematic
Review and Meta-Analysis. PLoS One. 2016 Oct 6;11(10):e0164034. doi: 10.1371/journal.pone.0164034.
53. Orgeur M, Brosch R. Evolution of virulence in the Mycobacterium tuberculosis complex. Curr Opin Microbiol. 2018 Feb;41:68-75.
doi: 10.1016/j.mib.2017.11.021.
54. Pai M, Gokhale K, Joshi R, Dogra S, Kalantri S, Mendiratta DK, Narang P, Daley CL, Granich RM, Mazurek GH, Reingold AL, Riley LW, Colford JM Jr. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA. 2005 Jun 8;293(22):2746-55. doi: 10.1001/jama.293.22.2746.
55. Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, Schoolnik GK, Sherman DR. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol. 2003 May;48(3):833-43. doi: 10.1046/j.1365-2958.2003.03474.x.
56. Peters C, Kozak A, Nienhaus A, Schablon A. Risk of Occupational Latent Tuberculosis Infection among Health Personnel Measured by Interferon-Gamma
Release Assays in Low Incidence Countries-A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2020 Jan 16;17(2):581.
doi: 10.3390/ijerph17020581.
57. Reves R, Daley CL. Screening for Latent Tuberculosis Infection: A Key Step Toward Achieving Tuberculosis Elimination in the United States. JAMA Intern Med. 2016 Oct 1;176(10):1439-1440. doi: 10.1001/jamainternmed. 2016.5464.
58. Rosales-Klintz S, Bruchfeld J, Haas W, Heldal E, Houben RMGJ, van Kessel F. et al. Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area. Eur Respir J. 2019 Jan 17;53(1):1802077. doi: 10.1183/13993003.02077-2018.
59. Rustad TR, Harrell MI, Liao R, Sherman DR. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One. 2008 Jan 30;3(1):e1502. doi: 10.1371/journal.pone.0001502.
60. Saelens JW, Viswanathan G, Tobin DM. Mycobacterial Evolution Intersects With Host Tolerance. Front Immunol. 2019 Mar 22;10:528. doi: 10.3389/fimmu.2019.00528.
61. Salina EG, Makarov V. Mycobacterium tuberculosis Dormancy: How to Fight a Hidden Danger. Microorganisms. 2022 Nov 25;10(12):2334. doi: 10.3390/microorganisms 10122334.
62. Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, et al.. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet
Infect Dis 2021; 21: 354–365. doi: 10.1016/S1473-3099(20)30914-2.
63. Seedat F, Hargreaves S, Nellums LB, Ouyang J, Brown M, Friedland JS. How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review. Lancet Infect Dis. 2018 Sep;18(9):e259-e271. doi: 10.1016/S1473-3099(18)30117-8.
64. Vekemans J, Lienhardt C, Sillah JS, Wheeler JG, Lahai GP, Doherty MT, Corrah T, Andersen P, McAdam KP, Marchant A. Tuberculosis contacts but not
patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia. Infect Immun. 2001 Oct;69(10):6554-7. doi: 10.1128/IAI.69.10.6554-6557.2001.
65. WHO. Global Tuberculosis Report 2015. Geneva: 2015. http://www.who.int/tb/ publications/global_report/en/ (Accessed 23 September 2016)
66. WHO. Latent TB infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018а.
67. WHO. Global Tuberculosis Report 2018b. www.who.int/tb/publications/global _report/ en/Date last accessed: February 28, 2019. Date last updated:
February 28, 2019.
68. Xu M, Lu W, Li T, Li J, Du W, Wu Q, Liu Q, Yuan B, Lu J, Ding X. et al. Sensitivity, Specificity, and Safety of a Novel ESAT6-CFP10 Skin Test for Tuberculosis Infection in China: 2 Randomized, Self-Controlled, Parallel-Group Phase 2b Trials. Clin Infect Dis. 2022 Mar 1;74(4):668-677. doi: 10.1093/ cid/ciab472.
69. Zellweger JP, Sotgiu G, Corradi M, Durando P. The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and
perspectives to eliminate tuberculosis (TB). Med Lav. 2020 Jun 26;111(3):170-183. doi: 10.23749/mdl.v111i3.9983.
